Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine

• Published in: Vaccine Vol. 21; no. 21; pp. 2743 - 2746
• Main Authors: Oxford, John S, Al-Jabri, Ali A, Lambkin, Robert, Palache, A.M, Fleming, D.M
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 20.06.2003; Elsevier; Elsevier Limited
• Subjects: Adult; Age; Aged; Aged, 80 and over; Animals; Antibodies, Viral - immunology; Biological and medical sciences; Cell culture; Cell grown vaccine; Cell Line; Chick Embryo; Dogs; Eggs; Female; Fundamental and applied biological sciences. Psychology; Hepatitis; Humans; Immune response; Immunization; Immunization, Secondary; Influenza; Influenza A virus - immunology; Influenza B virus - immunology; Influenza vaccine seroconvert; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Injections, Intramuscular; Male; MDCK; Microbiology; Middle Aged; Mortality; Non-responders; Surveys and Questionnaires; Vaccination; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Virology; Cell grown vaccine; MDCK; Influenza vaccine seroconvert; Non-responders; Immunization; Vaccination; Orthomyxoviridae; Vaccine; Infection; Virus; Prevention; Immunoprophylaxis; Influenzavirus A; Influenza A virus; Viral disease; Influenza; Influenza A
• DOI: 10.1016/S0264-410X(03)00214-7
• ISSN: 0264-410X

We have investigated whether ‘at risk’ subjects who did not respond serologically during a pre-study vaccination with a commercial egg grown influenza sub-unit vaccine would respond to a subsequent vaccination with either a single dose of MDCK cell grown influenza vaccine or a standard egg grown influenza vaccine containing the same virus strains. We studied 48 non-responder subjects with a mean age 67.5, range: 34–82 years. In this non-responder group the increased immune response that was detected after boosting with an MDCK cell derived vaccine response was variable and relatively modest, except for the A/Texas strain in the vaccine. The proportion of subjects, with an HI titre of ≥40 (protective antibody titre) increased from 50 to 83% (A/Texas strain), from 13 to 25% (B/Harbin strain) and from 38 to 46% (A/Wuhan strain). In comparison a booster vaccination with egg-derived influenza vaccine resulted in an increase immune response with an HI antibody titre ≥40 for two of the three strains, namely from 17 to 58% for the B/Harbin strain and from 8 to 33% for the A/Wuhan strain.